vs
IMAX（IMAX）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
IMAX的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.7倍（$125.2M vs $75.5M），IMAX同比增速更快（35.1% vs 27.7%），IMAX自由现金流更多（$28.0M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 25.8%）
IMAX公司是加拿大的影视放映技术企业，1967年创立于蒙特利尔，总部位于多伦多地区，在纽约、洛杉矶均设有业务点。核心业务包括IMAX摄影机与放映系统的设计制造，同时面向全球合作影院提供影片开发、制作、后期及发行服务，是沉浸式观影技术领域的领先企业。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
IMAX vs PBYI — 直观对比
营收规模更大
IMAX
是对方的1.7倍
$75.5M
营收增速更快
IMAX
高出7.4%
27.7%
自由现金流更多
IMAX
多$13.6M
$14.4M
两年增速更快
PBYI
近两年复合增速
25.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $125.2M | $75.5M |
| 净利润 | $637.0K | — |
| 毛利率 | 57.6% | 69.3% |
| 营业利润率 | 19.3% | 22.7% |
| 净利率 | 0.5% | — |
| 营收同比 | 35.1% | 27.7% |
| 净利润同比 | -88.0% | — |
| 每股收益（稀释后） | $0.02 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMAXPBYI
| Q4 25 | $125.2M | $75.5M | ||
| Q3 25 | $106.7M | $54.5M | ||
| Q2 25 | $91.7M | $52.4M | ||
| Q1 25 | $86.7M | $46.0M | ||
| Q4 24 | $92.7M | $59.1M | ||
| Q3 24 | $91.5M | $80.5M | ||
| Q2 24 | $89.0M | $47.1M | ||
| Q1 24 | $79.1M | $43.8M |
净利润IMAXPBYI
| Q4 25 | $637.0K | — | ||
| Q3 25 | $20.7M | $8.8M | ||
| Q2 25 | $11.3M | $5.9M | ||
| Q1 25 | $2.3M | $3.0M | ||
| Q4 24 | $5.3M | — | ||
| Q3 24 | $13.9M | $20.3M | ||
| Q2 24 | $3.6M | $-4.5M | ||
| Q1 24 | $3.3M | $-4.8M |
毛利率IMAXPBYI
| Q4 25 | 57.6% | 69.3% | ||
| Q3 25 | 63.1% | 77.7% | ||
| Q2 25 | 58.5% | 76.5% | ||
| Q1 25 | 61.4% | 77.1% | ||
| Q4 24 | 52.2% | 76.4% | ||
| Q3 24 | 55.8% | 63.9% | ||
| Q2 24 | 49.4% | 77.4% | ||
| Q1 24 | 59.3% | 75.5% |
营业利润率IMAXPBYI
| Q4 25 | 19.3% | 22.7% | ||
| Q3 25 | 27.2% | 17.6% | ||
| Q2 25 | 15.6% | 12.7% | ||
| Q1 25 | 19.3% | 8.7% | ||
| Q4 24 | 10.3% | 22.6% | ||
| Q3 24 | 21.2% | 27.4% | ||
| Q2 24 | 3.2% | -4.6% | ||
| Q1 24 | 15.3% | -5.3% |
净利率IMAXPBYI
| Q4 25 | 0.5% | — | ||
| Q3 25 | 19.4% | 16.2% | ||
| Q2 25 | 12.3% | 11.2% | ||
| Q1 25 | 2.7% | 6.5% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 15.2% | 25.2% | ||
| Q2 24 | 4.0% | -9.6% | ||
| Q1 24 | 4.1% | -11.0% |
每股收益（稀释后）IMAXPBYI
| Q4 25 | $0.02 | $0.26 | ||
| Q3 25 | $0.37 | $0.17 | ||
| Q2 25 | $0.20 | $0.12 | ||
| Q1 25 | $0.04 | $0.06 | ||
| Q4 24 | $0.09 | $0.40 | ||
| Q3 24 | $0.26 | $0.41 | ||
| Q2 24 | $0.07 | $-0.09 | ||
| Q1 24 | $0.06 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.2M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $337.9M | $130.3M |
| 总资产 | $894.0M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资IMAXPBYI
| Q4 25 | $151.2M | $97.5M | ||
| Q3 25 | $143.1M | $94.4M | ||
| Q2 25 | $109.3M | $96.0M | ||
| Q1 25 | $97.1M | $93.2M | ||
| Q4 24 | $100.6M | $101.0M | ||
| Q3 24 | $104.5M | $96.7M | ||
| Q2 24 | $91.6M | $96.8M | ||
| Q1 24 | $81.0M | $107.2M |
总债务IMAXPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益IMAXPBYI
| Q4 25 | $337.9M | $130.3M | ||
| Q3 25 | $349.5M | $115.3M | ||
| Q2 25 | $320.4M | $104.7M | ||
| Q1 25 | $299.5M | $97.1M | ||
| Q4 24 | $299.5M | $92.1M | ||
| Q3 24 | $289.4M | $71.1M | ||
| Q2 24 | $267.2M | $48.5M | ||
| Q1 24 | $258.8M | $51.0M |
总资产IMAXPBYI
| Q4 25 | $894.0M | $216.3M | ||
| Q3 25 | $889.6M | $202.9M | ||
| Q2 25 | $868.6M | $194.9M | ||
| Q1 25 | $848.3M | $196.2M | ||
| Q4 24 | $830.4M | $213.3M | ||
| Q3 24 | $847.6M | $220.7M | ||
| Q2 24 | $827.4M | $205.0M | ||
| Q1 24 | $824.1M | $214.1M |
负债/权益比IMAXPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $28.0M | $14.4M |
| 自由现金流率自由现金流/营收 | 22.3% | 19.1% |
| 资本支出强度资本支出/营收 | 1.1% | 0.0% |
| 现金转化率经营现金流/净利润 | 46.11× | — |
| 过去12个月自由现金流最近4个季度 | $118.9M | $41.7M |
8季度趋势，按日历期对齐
经营现金流IMAXPBYI
| Q4 25 | $29.4M | $14.4M | ||
| Q3 25 | $67.5M | $9.7M | ||
| Q2 25 | $23.2M | $14.1M | ||
| Q1 25 | $7.0M | $3.6M | ||
| Q4 24 | $11.5M | $15.6M | ||
| Q3 24 | $35.3M | $11.0M | ||
| Q2 24 | $35.0M | $1.0M | ||
| Q1 24 | $-11.0M | $11.2M |
自由现金流IMAXPBYI
| Q4 25 | $28.0M | $14.4M | ||
| Q3 25 | $64.8M | $9.7M | ||
| Q2 25 | $20.9M | $14.1M | ||
| Q1 25 | $5.3M | $3.6M | ||
| Q4 24 | $6.9M | $15.6M | ||
| Q3 24 | $34.2M | $11.0M | ||
| Q2 24 | $33.5M | $1.0M | ||
| Q1 24 | $-12.1M | — |
自由现金流率IMAXPBYI
| Q4 25 | 22.3% | 19.1% | ||
| Q3 25 | 60.7% | 17.7% | ||
| Q2 25 | 22.8% | 26.8% | ||
| Q1 25 | 6.1% | 7.7% | ||
| Q4 24 | 7.4% | 26.4% | ||
| Q3 24 | 37.3% | 13.7% | ||
| Q2 24 | 37.6% | 2.1% | ||
| Q1 24 | -15.3% | — |
资本支出强度IMAXPBYI
| Q4 25 | 1.1% | 0.0% | ||
| Q3 25 | 2.6% | 0.0% | ||
| Q2 25 | 2.6% | 0.0% | ||
| Q1 25 | 1.9% | 0.1% | ||
| Q4 24 | 5.0% | 0.0% | ||
| Q3 24 | 1.2% | 0.0% | ||
| Q2 24 | 1.8% | 0.0% | ||
| Q1 24 | 1.4% | 0.0% |
现金转化率IMAXPBYI
| Q4 25 | 46.11× | — | ||
| Q3 25 | 3.27× | 1.10× | ||
| Q2 25 | 2.06× | 2.41× | ||
| Q1 25 | 2.99× | 1.21× | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | 0.54× | ||
| Q2 24 | 9.78× | — | ||
| Q1 24 | -3.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
PBYI
暂无分部数据
